ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/BTK
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/BTK
6
trial(s) found.
NCT06876649
Paed
Phase 4
Recruiting
A Master Protocol to Evaluate the Long-Term Safety of Pirtobrutinib
BTK inhibitor
Chronic lymphocytic leukaemia
Non-Hodgkin's lymphoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT06788509
Advanced
Phase 1
Enrolling by invitation
An Open Label, Rollover Platform Study for Continued Study Treatment and Ongoing Safety Monitoring (
PLATFORMPACAN1001
)
BTK inhibitor
Ibrutinib
JNJ-80948543
MALT1 inhibitor
Rezetamig
Safimaltib
bispecific T-cell engager,CD22-targeting
cancer therapy
cancer therapy,BTK-targeting
cancer therapy,CD20-targeting
cancer therapy,CD22-targeting
cancer therapy,CD79b-targeting
cancer therapy,MALT1-targeting
immuno-oncology therapy,CD20-targeting
immuno-oncology therapy,CD22-targeting
immuno-oncology therapy,CD79b-targeting
therapeutic modality,bispecific T-cell engager
therapeutic modality,bispecific antibody
trispecific CD79b/CD20/CD3 antibody
+ BTK inhibitor
Cancer
Castrate-resistant prostate cancer
Leukaemia
Lymphoma
Myelodysplastic syndrome
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
WA
6009 - Nedlands - Linear Clinical Research
NCT06634589
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies (
BGB-16673-104
)
BTK PROTAC degrader
B-cell lymphoma
NSW
2217 - Kogarah - St George Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT05947851
Advanced
Phase 3
Recruiting
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010) (
1026-010
)
BTK inhibitor
Bcl2 inhibitor
anti-CD20 monoclonal antibody
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
VIC
3021 - St Albans - Western Health - Sunshine Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT04728893
Advanced
Phase 2
Recruiting
A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies (
1026-003
)
BTK inhibitor
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma
Follicular lymphoma
Mantle cell lymphoma
Marginal zone lymphoma
Small lymphocytic lymphoma
Waldenström Macroglobulinaemia
NSW
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (COMPLETED)
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
ACTRN12625000965404
Haem
Phase 3
Not yet recruiting
ALLG CLL10/CLLRT2: A prospective, open-label, randomised, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R-(mini)-CHOP for treatment of patients with Richter Transformation (
CLL-RT2
)
BTK inhibitor
bispecific T-cell engager,CD20-targeting
Cancer
Chronic lymphocytic leukaemia
Diffuse large B-cell lymphoma,Richter's transformation
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (4)
Enrolling by invitation (1)
Not yet recruiting (1)
Recruitment Country and State
VIC (4)
WA (4)
SA (2)
NSW (2)
NZ (1)
QLD (1)
Phase
Phase 1 (1)
Phase 1 / Phase 2 (1)
Phase 2 (1)
Phase 3 (2)
Phase 4 (1)
Trial Type
Advanced (4)
Paed (1)
Haem (1)
Cancer Therapy Class
BTK
100%
CD20
67%
Bcl2
33%
CD22
17%
CD79b
17%
MALT1
17%
Facility
3000 - Melbourne - Peter MacCallum Cancer Centre (2)
6009 - Nedlands - Linear Clinical Research (2)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (2)
5042 - Bedford Park - Flinders Medical Centre (1)
2031 - Randwick - Scientia Clinical Research Ltd (1)
2217 - Kogarah - St George Hospital (1)
3004 - Melbourne, Southbank - Alfred Health (1)
3168 - Clayton - Monash Medical Centre (1)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
NZ.0622 - Takapuna - North Shore Hospital (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
3021 - St Albans - Western Health - Sunshine Hospital (1)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (1)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (1)
3128 - Box Hill - Box Hill Hospital - Eastern Health (1)
Cancer Type
Cancer
Haematological malignancy
Lymphoma
B-cell malignancy
Leukaemia
Mature B-cell malignancy
Non-Hodgkin's lymphoma
Chronic lymphocytic leukaemia
Lymphoid leukaemia
B-cell lymphoma
Small lymphocytic lymphoma
Diffuse large B-cell lymphoma
High-grade B-cell lymphoma
Castrate-resistant prostate cancer
Male genital cancers
Myelodysplastic syndrome
Myeloproliferative neoplasm
Prostate adenocarcinoma
Prostate cancer
Solid tumour
Urogenital cancer
Follicular lymphoma
Mantle cell lymphoma
Marginal zone lymphoma
Waldenström Macroglobulinaemia
Diffuse large B-cell lymphoma,Richter's transformation
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy